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Abstract 
Aims: We analyze the possible clinical differences between bone jaw exposed areas in ONJ (osteonecrosis of the 
jaws) and ORN (osteoradionecrosis).
Patients and method: Group 1 was composed with 53 ONJ cases and group 2 with 20 ORN cases. In both groups 
we analyzed, the major size of the exposed bone areas, the number of exposed areas, the location on the jaws and 
the presence of others associated and severe complications, such as skin fistulas and jaw fractures. We also inves-
tigated the possible local aetiology or trigger factor of the lesions.
Results: The major size of the bone exposed areas was  2.29±2.02(mean ± std.dev) in group 1 and 2.7±2.9 (mean ± 
std.dev) in group 2 (p>0.05). The number of exposed areas was 1.8±1.34 (mean ± std.dev) in group 1 and 1.2±0.55 
(mean ± std.dev) in group 2 (p>0.05). There were more fractures in the second group (20%) (p<0.05), and skin 
fistulas (35%) (p<0.05). We found more patients in group 1 in which the dental extraction was the local aetiology 
of the bone necrosis (35 cases, 66.03%), while in group 2 there were 8 (40%) (p<0.05).
Conclusions: In our study with ONJ there were not differences in the major size of the bone exposed areas, but 
there were more lesions per patient than in group with ORN. The severity of the complications, such as jaw frac-
tures and skin fistulas were higher in ORN, and in this group it was more frequent the spontaneous lesions than in 
the ONJ where it is more frequent following dental extractions.
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Introduction
Bisphosphonate treatment for malignant diseases or 
osteoporosis is common. In the case of malignant dis-
eases, bisphosphonates are usually given intravenously 
to manage hypercalcemia and bone metastases, such as 
in the case of multiple myeloma and metastatic breast 
cancer (1,2). In the case of osteoporosis these drugs are 
prescribed orally (3,4).
Marx in 2003 (5) reported some of the first described 
cases of osteonecrosis (osteochemonecrosis) of the jaws 
(ONJ) As a severe complication from the use of bispho-
sphonates. Since then there have been many reports 
(6-11) and Pubmed contains more than 195 articles on 
this subject. 
In ONJ, the jaw bone is exposed with one or several 
necrotic areas, some cases arising after surgery such as 
a tooth extraction, but in other cases the origin is un-
known (12-14).
ONJ is similar in clinical appearance to osteoradion-
ecrosis (ORN), where the lesions develop after radio-
therapy to the head and neck area, typically for the man-
agement of malignant tumours. (15-19). ORN mainly 
occurs when the radiation dose exceeds 65 Gy. The risk 
to ORN last for many months after radiation treatment. 
(15).
Although both conditions, ONJ and ORN have been 
widely described there are no substantial studies pub-
lished that compare them in terms of the characteristics 
of the bone lesions, their aetiology and other clinical as-
pects. The aim of this study was to determine what are 
the differences if any between ONJ and ORN.
Material and Methods
We studied two groups. The first (group 1) composed of 
53 patients who had developed osteochemonecrosis of 
the jaws caused by intravenous bisphosphonates for the 
treatment of malignant diseases (ONJ). We followed the 
accepted criteria (20) to establish the diagnosis of ONJ. 
Group 2 was a sample of 20 patients with osteoradion-
ecrosis of the jaws (ORN), the diagnosis being estab-
lished following the criteria described by Thorn et al. 
(15).
In both groups we examined the overall size of the ex-
posed bone area, the number of exposed areas, other 
clinical characteristics such as the location in the jaws 
and the presence of other severe complications, such as 
skin fistulas and jaw fractures. We also investigated the 
possible local aetiology or trigger factors of the lesions.
We analyzed the possible association between variables 
by the x2 test and the Student t test to compare the dif-
ferences between the means in both groups, when the 
data follow a normal distribution. We considered a dif-
ference statistically significant when p was < 0.05.
Results
Most of the patients in Group 1 (ONJ) had either meta-
static breast carcinoma or multiple myeloma (Table 1). 
In 50 cases the number of months on bisphosphonate 
treatment was known, the mean being 33.4 ± 17.8 (std. 
deviation), (range 10 to 84 months). In most instances 
(51 out of the 53 cases: 96.2%), the patients had been 
treated with Zoledronic acid (Zometa ®) while there 
were 18 (34%) cases on Pamidronate (Aredia ®). 
In Group 2 (ORN), all the patients had developed at 
least one ORN area, and most patients (18 cases; 90%) 
had oral squamous cell carcinoma and the rest had oral 
lymphomas. The mean radiation dose was 64.85 Gy ± 
7.9 (std. deviation), (range 48 Gy to 85 Gy). 
The mean ages in both Groups were not statistically 
different (p > 0.05) but there was a significantly higher 
number of females in Group 1 (p < 0.05) (Table 2).
Tobacco and alcohol habits; exposed bone locations, 
number, and overall size; and other clinical character-
istics are shown in table 2.
Discussion
Osteonecrosis caused by bisphosphonates (ONJ) or ra-
diotherapy (ONR) manifest primarily by bone exposure. 
(5,15) Habits such as tobacco and alcohol have been as-
sociated with an increased risk of developing areas of 
ORN but have not been recorded in ONJ. We found in 
our studio that 22.6% ONJ patients were smokers, com-
pared with 60% in the ORN group (p< 0.05).
Thorn et al. (15) found 92% of patients with ORN were 
smokers or had been before their radiotherapy. At the 
time of exposure bone 63 (82%) cases were smokers and 
62% of those had a consumption of 10 or more ciga-
Number of 
cases %
Tumor
Breast 25 47.2
Multiple myeloma 21 39.6
Prostate 5 9.4
Lung 1 1.9
Kidney 1 1.9
Bisphosphonate
Zoledronic acid
(Zometa ®) 51 96.2
Pamidronate
(Aredia ®) 35 66
Other drugs
Corticosteroids 20 41.7
Talidomide 5 10.4
Interpheron 7 14.6
Chemotherapy 46 95.6
Table 1. Tumor and drugs in group on bisphosphonates.
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rettes a day. With regard to alcohol consumption 54% 
patients consumed alcohol in varying amounts per day 
at the time of ORN. Kluth et al. (16) found a relationship 
between the continuous consumption of alcohol and to-
bacco and the development of ORN. Marx (12) reported 
that 83% of his patients with ORN were smokers. 
Several studies (5-9) have demonstrated the higher in-
cidence of ONJ in the mandible, both in intravenous 
and orally prescribed bisphosphonates, and we could 
not find differences in between ONJ and ORN in the 
location (p>0.05). ORN lesions are known to have a 
predilection for the molar area of the mandible (15, 21) 
though others found in the symphysis to be the most 
common location (17).  
In the present study we analyzed the overall size of 
bone lesions and did not find a difference between ONJ 
and ORN (p>0.05), the mean size being 2.29 cm in 
ONJ and 2.7 cm in ORN. Thorn et al. (15) measured 
the radiotransparency in the ortopantomograph in pa-
tients with ORN and found that almost half of the cases 
had between 2-5 cm2 (41%) followed by areas 0-2 cm2 
(34%), 5-10 cm2 (18%) and greater than 10 cm2 (8%). In 
patients with ONJ we found in our previously published 
study (9) that the average size of the exposed jaw bone 
areas was 1.96 cm. 
We also found in our previous article (9), a mean of 2.3 
exposed areas in each patient and a number of authors 
have reported a greater number of exposed bone areas in 
ONJ (5-8). In the present study the number of areas was 
higher in the ONJ group with an average of 1.8±1.34, 
while in the ORN it was 1.2±0.55 but the difference was 
not statistically significant.
In the present study fractures were found in 1.8% of our 
ONJ patients but significantly more frequently in 20% 
of ORN cases (p<0.05). In the case of ORN the study 
of Thorn (15) reported that the presence of pain in their 
ORN cases did not clearly correlate with the size of the 
lesion, but was always present when there were frac-
tures and fistulas (18). 
In the  present study extractions were the most impor-
tant aetiologic factor in ONJ but, in ORN, there were 
many cases (50%) in whom the lesions appeared spon-
taneously (Table 2). This is an important and statisti-
cally significant distinction between both processes. 
(p<0.05). Marx et al. (12) also reported that 37.8% of 
their patients with ONJ were associated with dental ex-
tractions, 29% due to periodontal disease and 11% to 
periodontal surgery. 
The present results differ from the comparative study 
conducted by Walter et al. (21) but with a lower number 
of cases in the ONJ group than in ours, where dental 
treatments were the trigger for ONJ in 13 out of 17 cas-
es, but in the ORN group the importance of the dental 
treatments as a trigger had less importance, being seen 
in only 14 of 45 cases. This difference is difficult to ex-
plain.
Group 1: Bisphosphonates
 (53 cases)
Group 2: Osteoradionecrosis
(20 cases)
Age 63.4 62.2 t=0.42  p>0.05
Gender
Male Female Male Female
χ 2 = 10.37 p<0.05
20 (37.7%) 33 (62.3%) 16 (80%) 4 (20%)
Tobacco 12 (22.6%) 12 (60%) χ 2 = 9.32 p<0.05
Alcohol 10 (19.2%) 8(40%) χ 2 = 3.23 p=0.06
Location
Mandible
44(83.01%) 16(80%) χ 2 = 3.34 p=0.81
Upper jaw
20(37.7%) 4(20%) χ 2 = 2.59 p=0.62
Number of the bone 
exposed areas 1.8±1.34 (mean ± std.dev) 1.2±0.55 (mean ± std.dev) t=1.79  p=0.07
Major size of the 
bone exposed areas 2.29±2.02(mean ± std.dev) 2.7±2.9 (mean ± std.dev) t=-0.62  p>0.05
Jaw fractures 2(1.8%) 4(20%) χ 2 = 7.14 p<0.05
Skin fistulas 1(3.7%) 7(35%) χ 2 = 12.53 p<0.05
Etiology
Ext. Imp. Prot. Unk. Ext. Imp. Prot. Unk.
35 1 5 12 8 - 2 10 χ 2 = 12.53 p<0.05
Table 2. Comparation of the clinical characteristics in ONJ and ORN.
Ext.: Extraction; Imp.: Implant; Prot.: Prosthesis; Unk.: Unknown etiology
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